

Microbiome Therapeutics: Global Markets

Market Research Report | 2023-01-24 | 175 pages | BCC Research

AVAILABLE LICENSES:

- Single User License \$5500.00
- 2-5 Users License \$6600.00
- Site License \$7920.00
- Enterprise License \$9504.00

Report description:

Description

Report Scope:

BCC Research's new report, Microbiome Therapeutics: Global Markets, provides a comprehensive analysis of the microbiome therapeutics market in global context, including market forecasts and sales through 2027. The report analyzes the market by segmenting it into the various types of microbiome therapeutics, based on the strategies used for treatment: additive (fecal matter transplants or FMTs, live biotherapeutic products or LBPs), modulatory (postbiotics, prebiotics) and subtractive microbiome therapeutics (phages and antimicrobials). This study surveys the microbiome therapeutics market by application or disease segment: infectious diseases, metabolic diseases, cancer, gut-brain axis, and others. The market is assessed in the following geographic regions: North America, Europe, and emerging markets. Emerging markets include countries like India, China, Korea, Taiwan, Africa, Australia, New Zealand, Canada, and Latin America.

The report features leading clinical trials indicating the status and phase of development. New developments and patents are boosting growth of this market in the global context.

The new BCC report provides comprehensive profiles of market players in the industry. The industry structure chapter focuses on the changing market trends, market players and leading pipeline candidates. This chapter covers influential mergers and acquisitions and other collaborations or partnerships that happened during the evaluation period of this report.

Strengths, weaknesses, threats, and opportunities that are expected to play a role in the microbiome therapeutics market are evaluated in detail.

The markets for prebiotics and probiotics labeled as nutritional or dietary supplements are excluded from this report. Prebiotics

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

and probiotics are included when used in the context of microbiome therapy.

Report Includes:

- 32 data tables and 44 additional tables
- An up-to-date overview and analysis of the global and regional markets for microbiome therapeutics
- Analyses of the global market trends, with historic market revenue (sales data) for 2021, estimates for 2022 and 2023, and projections of compound annual growth rates (CAGRs) through 2027
- Discussion of the industry growth driving factors and major technology challenges and issues affecting the market for microbiome therapeutics as a basis for projecting demand over the next few years (2022-2027)
- Estimation of the actual market size and revenue forecast for global microbiome therapeutics market in USD million terms, and corresponding market share analysis by technology type, application, and region
- Highlights of this innovation driven market covering current trends in genome sequencing industry, disease areas of application, clinical trials and their stages, and recent breakthrough innovations etc.
- Assessment of the recent industry structure for microbiome therapeutics, ongoing research (R&D) activities, analysis of competitive environment, and the COVID-19 impact on the marketplace
- Review of the patents and patent applications on microbiome therapeutics, and related scientific publications during the analysis period
- Competitive landscape of this market featuring leading biopharmaceutical companies, their product portfolios, financial updates, and market share analysis based on recent segmental revenues
- Profile description of the major market participants, including Assembly Biosciences, Finch Therapeutics, Second Genome, Evelo Biosciences, Ysopia Bioscience and Evelo Biosciences

Executive Summary

Summary:

The microbiome has become a buzz word and attracted millions of dollars in federal grants, awards and funding from venture capitalists. Technological advancements in next-generation sequencing and data analytics clubbed with modern approaches of systems biology and genetic engineering have greatly expanded the knowledge of commensal microbial populations and interactions with human hosts.

The Human Microbiome Project (HMP), MetaHIT and other independent efforts fueling the exploration of microbiome and its association with human health have led to a research explosion in this area in the last decade. Myriad studies abound showing how the microbiome mediate many physiological processes (metabolism, nutrition, immunity, etc.). Many clinical studies show alterations in microbial populations or microbial dysbiosis can lead to disease. Restoration of the microbiome addresses many unmet medical needs. Diseases that still do not have definitive cures or with available treatments that are either not satisfactory or are cost-prohibitive, are actively targeted by microbiome therapeutics.

There are many active players in the field of microbiome therapeutics, ranging from discovery and clinical-stage to late-stage companies that are exploiting different approaches to modulate the microbiome. Fecal microbial transplants (FMTs) have been in practice for some time and the use of live biotherapeutic products (LBPs) in the form of single strains or microbial consortia is a popular strategy with targeted mechanisms and controlled production processes. The development of small molecule drugs (postbiotics) and the use of phages are being actively explored.

Currently, no microbiome therapeutic is approved in the U.S. or in any other market. There are some candidates in Phase 3 trials (Seres Therapeutics SER109 and Rebiotix's RBX2660) that are being evaluated for the treatment of recurrent *Clostridium difficile*

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

infection. Despite an expansive patent portfolio and a large number of clinical trials in the field of microbiome therapeutics, the market is facing some challenges. The absence of any regulatory framework brings uncertainty for many developers in this novel market. The complexity of the human microbiome and variations among different individuals add to difficulties in the design of clinical trials. Additional hurdles are expected during scaling.

For the microbiome therapeutics market to grow, a strong collaborative effort is needed from all stakeholders, including the regulatory agencies. Statistically-relevant results and proof-of-concept studies driven by technological advancements in biomarkers, functional assays and computational biology are required that will eventually pave the way for product approvals.

Table of Contents:

Table of Contents

Chapter 1 Introduction

1.1 Study Goals and Objectives

1.2 Reasons for Doing This Study

1.3 What's New in This Report?

1.4 Scope of Report

1.5 Information Sources

1.6 Methodology

1.7 Geographic Breakdown

1.8 Analyst's Credentials

1.9 BCC Custom Research

1.10 Related BCC Research Reports

Chapter 2 Summary and Highlights

2.1 Key Highlights

Chapter 3 Market and Technology Background

3.1 Benefits

3.2 The Human Microbiome

3.2.1 Different Microbiomes in Humans

3.2.2 Microbiome, Human Health and Disease

3.2.3 Technologies Aiding Microbiome Research

3.2.4 Microbiome Research Projects

3.3 Microbiome Therapeutics

3.3.1 Strategies for the Development of Microbiome Therapeutics

3.3.2 Microbiome Therapeutics Disease Areas

3.3.3 Regulatory Landscape for Microbiome Therapeutics

Chapter 4 Market Breakdown by Type of Therapeutic

4.1 Introduction

4.2 Market Overview

4.2.1 Market Revenue

4.2.2 Market Shares

4.3 Additive Microbiome Therapeutics

4.3.1 Fecal Microbiota Transplants (FMTs)

4.3.2 Live Biotherapeutic Products (LBPs)

4.3.3 Market Overview

4.3.4 Market Revenue

4.3.5 Market Shares

4.4 Modulatory Microbiome Therapeutics

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.4.1 Mechanism of Action
- 4.4.2 Current Status
- 4.4.3 Market Overview
- 4.4.4 Market Revenue
- 4.4.5 Market Shares
- 4.5 Subtractive Microbiome Therapeutics
 - 4.5.1 Mechanism of Action
 - 4.5.2 Current Status
 - 4.5.3 Market Overview
 - 4.5.4 Market Revenue
 - 4.5.5 Market Shares
- Chapter 5 Market Breakdown by Application
 - 5.1 Introduction
 - 5.1.1 Market Revenue
 - 5.1.2 Market Shares
 - 5.2 Infections
 - 5.2.1 Clostridium Difficile Infection (CDI)
 - 5.2.2 Urinary Tract Infection (UTI)
 - 5.2.3 COVID-19
 - 5.2.4 Market Overview
 - 5.2.5 Market Revenue
 - 5.3 Gastrointestinal (GIT) Diseases
 - 5.3.1 Market Overview
 - 5.3.2 Market Revenue
 - 5.4 Metabolic Diseases
 - 5.4.1 Market Overview
 - 5.4.2 Market Revenue
 - 5.5 Cancer
 - 5.5.1 Market Overview
 - 5.5.2 Market Revenue
 - 5.6 Gut-Brain Axis Diseases
 - 5.6.1 Market Overview
 - 5.6.2 Market Revenue
 - 5.7 Other Diseases
 - 5.7.1 Market Overview
 - 5.7.2 Market Revenue
 - 5.8 Regional Markets Globally
 - 5.8.1 Market Shares
- Chapter 6 Industry Structure
 - 6.1 Investment in Microbiome Therapeutics
 - 6.1.1 Public Funding Initiatives
 - 6.1.2 Private Funding Initiatives
 - 6.2 Collaborations and Partnerships
 - 6.3 Licensing and Manufacturing Agreements
 - 6.4 Mergers and Acquisitions
 - 6.5 Leading Market Players in the Market for Microbiome Therapeutics
 - 6.5.1 Leading Market Players in Market for Additive Microbiome Therapeutics

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.5.2 Leading Market Players in the Market for Modulatory Microbiome Therapeutics
- 6.5.3 Leading Market Players in the Market for Subtractive Microbiome Therapeutics
- 6.6 BCC Research Select Insights from Industry Leaders
- Chapter 7 Patent Analysis
 - 7.1 Patent Analysis
 - 7.1.1 Patents by Year
 - 7.1.2 Patents by Type
 - 7.1.3 Patents by Type of Disease
 - 7.1.4 Patents by Company
 - 7.1.5 Patents by Country
 - 7.1.6 Patents by Assignee
- Chapter 8 Clinical Trials
 - 8.1 Clinical Trials by Disease Category
 - 8.1.1 Distribution Shares of Clinical Trials
 - 8.2 Clinical Trials by Type of Therapeutic
 - 8.2.1 Distribution Shares of Clinical Trials by Type of Therapeutic
 - 8.3 Clinical Trials by Company
 - 8.3.1 Distribution Shares of Clinical Trials by Company
 - 8.3.2 Microbiome Therapeutics in Discovery and Preclinical Development
 - 8.3.3 Microbiome Therapeutics in Phase 3 Clinical Trials
- Chapter 9 Analysis of Market Opportunities
 - 9.1 SWOT Analysis
 - 9.1.1 Strengths of Market for Microbiome Therapeutics
 - 9.1.2 Challenges in the Market for Microbiome Therapeutics
 - 9.1.3 Opportunities in the Market for Microbiome Therapeutics
 - 9.1.4 Threats to the Market for Microbiome Therapeutics
- Chapter 10 Company Profiles
 - 4D PHARMA
 - AO BIOME LLC
 - ASSEMBLY BIOSCIENCES INC.
 - ARMATA PHARMACEUTICALS
 - AZITRA INC.
 - BIOMICA
 - BIOMX
 - CHAIN BIOTECHNOLOGY LTD.
 - ELIGO BIOSCIENCE SAS
 - ENTEROME SA
 - EVELO BIOSCIENCES
 - FINCH THERAPEUTICS GROUP INC.
 - INTRALYTIX INC.
 - MAAT PHARMA
 - OSEL INC.
 - PYLUM BIOSCIENCES INC.
 - QUORUM INNOVATIONS LLC
 - REBIOTIX INC. (A FERRING COMPANY)
 - SECOND GENOME
 - SENDA BIOSCIENCES INC.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

SERES THERAPEUTICS INC.
SFA THERAPEUTICS INC.
SYNOLOGIC
THERIVA BIOLOGICS INC.
VEDANTA BIOSCIENCES INC.
YSOPIA BIOSCIENCE INC.
Chapter 11 Appendix: Acronyms

Microbiome Therapeutics: Global Markets

Market Research Report | 2023-01-24 | 175 pages | BCC Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5500.00
	2-5 Users License	\$6600.00
	Site License	\$7920.00
	Enterprise License	\$9504.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-06-09"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com